Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 5/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.38 |
| ▸ | KDR | P35968 | 8/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2211395 | 0.92 | FGFR2 (0.41) | FGFR2KDRMAPTLMNATP53 | |
| SCHEMBL2211466 | 0.87 | KDR (0.34) | PDGFRAKDRMAPTLMNATP53 | |
| SCHEMBL2209642 | 0.80 | KDR (0.49) | FGFR2PDGFRAKDRAURKAAURKB | |
| SCHEMBL2211004 | 0.80 | AURKA (0.54) | FGFR2RETPDGFRAKDRAURKA | |
| SCHEMBL2211093 | 0.80 | KDR (0.37) | PDGFRAKDRMAPTLMNATP53 | |
| SCHEMBL15663339 | 0.78 | FGFR2 (0.34) | FGFR2RETPDGFRAKDRAURKA | |
| SCHEMBL2204739 | 0.74 | AURKA (0.47) | FGFR2KDRAURKAAURKBTPX2 | |
| SCHEMBL2210511 | 0.72 | MAPT (0.52) | FGFR2KDRMAPTLMNATP53 | |
| SCHEMBL2211389 | 0.72 | MAP2K1 (0.55) | FGFR2RETPDGFRAKDRAURKA | |
| SCHEMBL15663394 | 0.69 | MAPT (0.47) | FGFR2PDGFRAKDRAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981891-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-07-19 | — | — | US | claimed |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2010-11-04 | — | — | US | claimed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | FGFR2 334/4885RET 325/4885PDGFRA 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.